Tolrestat
Encyclopedia
Tolrestat (AY-27773) is an aldose reductase inhibitor
which was approved for the control of certain diabetic complications.
While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth
in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase.
Aldose reductase inhibitor
Aldose reductase inhibitors are a class of drugs being studied as a way to prevent eye and nerve damage in people with diabetes.-Mechanism:Their target, aldose reductase, is an enzyme that is normally present in many other parts of the body, and catalyzes one of the steps in the sorbitol pathway...
which was approved for the control of certain diabetic complications.
While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval. It was discontinued by Wyeth
Wyeth
Wyeth, formerly one of the companies owned by American Home Products Corporation , was a pharmaceutical company. The company was based in Madison, New Jersey, USA...
in 1997 because of the risk of severe liver toxicity and death. It was sold under the tradename Alredase.